Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Enovix Corporation (ENVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Enovix Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Enovix Corporation trades at $5.09 (market cap $1.10B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 7.3× Enovix Corporation's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| BIO | ENVX | |
|---|---|---|
Market Cap | $8.04B | $1.10B |
Sector | Health | Technology |
52-Week High | $339.75 | $15.93 |
52-Week Low | $241.71 | $4.84 |
Enterprise Value | $7.85B | $1.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
ENVX trades at $4.95, down 4.81% with bearish technical signals despite recent earnings beats. The company shows negative profitability with -499.64% net margin and -$156.74M net loss for 2025, though revenue grew to $31.82M. Recent positive developments include the appointment of a former Apple operations leader as COO and progress in battery technology commercialization.
While analyst consensus remains bullish with a $12.75 price target, significant execution risks persist given negative cash flows and high valuation multiples. The stock presents high-risk speculation on Enovix's ability to scale production and achieve profitability in the competitive battery technology market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
